<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02173054</url>
  </required_header>
  <id_info>
    <org_study_id>Acne and adjuctive moisturizer</org_study_id>
    <nct_id>NCT02173054</nct_id>
  </id_info>
  <brief_title>An Efficiency of a Moisturizer Containing Licochalcone A, L-carnitine and 1,2-decanediol With Adapalene Gel in Acne</brief_title>
  <official_title>An Evaluator-blind, Randomized, Vehicle-controlled Efficiency of Adjunctive Usage of a Moisturizer Containing Licochalcone A, L-carnitine and 1,2-decanediol With Adapalene Gel for Improvement of Local Tolerance in Thai Acne Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mahidol University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acne is an inflammation of sebaceous glands and follicles. Applying topical treatments such
      as adapalene gel may cause irritant adverse effects. Hence, using a moisturizer is another
      way to protect or relieve this undesirable event. Moisturizers that have anti-inflammatory
      property could reduce irritant effects, emergent from using topical treatment and also reduce
      severity of acne.

      Research teams chose an adapalene gel to act as topical treatment for curing acne. It has
      anti-inflammatory and comedolytic effects and has fewer side effects than other groups of
      topical retinoic acids. However, peeling skin, redness skin, tingling sensation or itching
      sensation may occur if they are continually used for a long period. Thus, for the purpose of
      studying the efficacy of moisturizer containing licochalcone A, L-carnitine and
      1,2-decanediol in reducing irritant effect of using adapalene gel (Licochalcone A has
      anti-inflammatory effect, L-carnitine decrease sebum production and 1,2-decanediol has
      anti-bacterial effect).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators team research with patients by separate patients into 3 groups and compare
      among each other. In the first group use only adapalene gel, the second group use adapalene
      gel with moisturizer containing three substances mentioned above, and the last group use
      adapalene gel with placebo moisturizer. To compare outcomes among 3 groups, the investigators
      will measure degree of redness, scale, oily face, moist, number of acne, quality of life, and
      satisfaction after using moisturizer.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of Undesirable Effects</measure>
    <time_frame>2nd week, 4th week, and 8th week</time_frame>
    <description>Undesirable effects were evaluated from skin's condition/signs(erythema, dryness and scaling) are evaluated by dermatologist. (none; mild; moderate; severe) and subject interview/symptoms(stinging/burning and pruritis) are evaluated by participants.(none; mild; moderate; severe). There were assessed at 2nd week, 4th week, and 8th week.
The worst score of each parameter which was defined as the worst local tolerance score is demonstrated and compared among 3 groups as shown.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Skin Tolerability: Skin Sebum Content and Skin Hydration</measure>
    <time_frame>Skin tolerability was assessed at baseline and week 8. The changes of skin tolerability between baseline and 8th week of the 3 groups were compared.</time_frame>
    <description>Skin tolerability was assessed by measuring the skin surface sebum content, skin hydration with the Sebumeter SM815 and Corneometer CM825, respectively</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Skin Tolerability: Transepidermal Water Loss (TEWL)</measure>
    <time_frame>Skin tolerability was assessed at baseline and week 8. The changes of skin tolerability between baseline and 8th week of the 3 groups were compared.</time_frame>
    <description>Skin tolerability was assessed by measuring TEWL with the Tewameter TM300</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction of Severity of Acne</measure>
    <time_frame>baseline, 2nd week, 4th week and 8th week</time_frame>
    <description>Evaluation from mean counts of inflammatory, noninflammatory, and total acne lesions at baseline, and at 2, 4, and 8 weeks
Total acne lesions = inflammatory + noninflammatory acne lesions
Reduction of lesions counts are considered to be a better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of Severity of Acne: Acne Severity Index (ASI)</measure>
    <time_frame>baseline, 2nd week, 4th week and 8th week</time_frame>
    <description>The ASI score was calculated from the number of papules + (2 x pustules) + (comedones/4)
Decrease of ASI score are considered to be a better outcome</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Acne</condition>
  <arm_group>
    <arm_group_label>Adapalene gel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Evening
Wash face by prepared facial foam and dry your face
Apply adapalene gel all over the face</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adapalene gel with placebo moisturizer</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Morning
Wash face by prepared facial foam and dry their face
Apply placebo cream all over the face
Evening
Wash face by prepared facial foam and dry your face
Apply adapalene gel all over the face
Apply placebo cream all over the face</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adapalene gel with Eucerin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Morning
Wash face by prepared facial foam and dry their face
Apply Eucerin cream all over the face
Evening
Wash face by prepared facial foam and dry your face
Apply adapalene gel all over the face
Apply Eucerin cream all over the face</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Adapalene gel with Eucerin</intervention_name>
    <description>Eucerin: 2 fingertip unit to cover all over the face twice a day. Adapalene gel: 2 fingertip unit to cover all over the face before going to bed</description>
    <arm_group_label>Adapalene gel with Eucerin</arm_group_label>
    <other_name>licochalcone A + L-carnitine + decanediol (Eucerin)</other_name>
    <other_name>Adapalene gel (Differin)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Adapalene gel</intervention_name>
    <description>Adapalene gel: 2 fingertip unit to cover all over the face before going to bed</description>
    <arm_group_label>Adapalene gel</arm_group_label>
    <other_name>Adapalene gel (Differin)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Adapalene gel with placebo moisturizer</intervention_name>
    <description>Placebo: 2 fingertip unit to cover all over the face twice a day. Adapalene gel: 2 fingertip unit to cover all over the face before going to bed</description>
    <arm_group_label>Adapalene gel with placebo moisturizer</arm_group_label>
    <other_name>â€¢Adapalene gel (Differin)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18 years old or above

          2. Participants have to control the birth for example, condom method, intrauterine device
             method before participate in the research at least 1 month until 6 months after
             research finish.

          3. being diagnosed acne vulgaris by dermatologist in mild to moderate degree based on
             Investigators' Global Assessment scale of FDA

        Exclusion Criteria:

          1. Use oral or injected antibiotics or other oral medicine treating acne for example,
             isotretinoin, oral contraceptives, or spironolactone group during 4 weeks before
             participate this research

          2. Have other active skin diseases at face during 2 weeks before participate the research

          3. Allergic to adapalene gel and moisturizer

          4. Have severe or uncontrolled underlying diseases

          5. Getting pregnant or during breast feeding

          6. Other types of acne(not acne vulgaris)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Papapit Tuchinda, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mahidol University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Siriraj Hospital Mahidol Univeristy</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 18, 2014</study_first_submitted>
  <study_first_submitted_qc>June 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2014</study_first_posted>
  <results_first_submitted>July 29, 2015</results_first_submitted>
  <results_first_submitted_qc>January 29, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 26, 2016</results_first_posted>
  <last_update_submitted>November 28, 2016</last_update_submitted>
  <last_update_submitted_qc>November 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acne</keyword>
  <keyword>Moisturizer</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Irritation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adapalene</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The recruitment period: between June 2014 and December 2014 Location: Department of Dermatology, Siriraj Hospital, Mahidol University, Thailand</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Adapalene Gel</title>
          <description>Evening
Wash face by prepared facial foam and dry your face
Apply adapalene gel all over the face
Adapalene gel: Adapalene gel: 2 fingertip unit to cover all over the face before going to bed</description>
        </group>
        <group group_id="P2">
          <title>Adapalene Gel With Placebo Moisturizer</title>
          <description>Morning
Wash face by prepared facial foam and dry their face
Apply placebo cream all over the face
Evening
Wash face by prepared facial foam and dry your face
Apply adapalene gel all over the face
Apply placebo cream all over the face
Adapalene gel with placebo moisturizer: Placebo: 2 fingertip unit to cover all over the face twice a day.
Adapalene gel: 2 fingertip unit to cover all over the face before going to bed</description>
        </group>
        <group group_id="P3">
          <title>Adapalene Gel With Eucerin</title>
          <description>Morning
Wash face by prepared facial foam and dry their face
Apply Eucerin cream all over the face
Evening
Wash face by prepared facial foam and dry your face
Apply adapalene gel all over the face
Apply Eucerin cream all over the face
Adapalene gel with Eucerin: Eucerin: 2 fingertip unit to cover all over the face twice a day.
Adapalene gel: 2 fingertip unit to cover all over the face before going to bed</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>lack of compliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Adapalene Gel</title>
          <description>Evening
Wash face by prepared facial foam and dry your face
Apply adapalene gel all over the face
Adapalene gel: Adapalene gel: 2 fingertip unit to cover all over the face before going to bed</description>
        </group>
        <group group_id="B2">
          <title>Adapalene Gel With Placebo Moisturizer</title>
          <description>Morning
Wash face by prepared facial foam and dry their face
Apply placebo cream all over the face
Evening
Wash face by prepared facial foam and dry your face
Apply adapalene gel all over the face
Apply placebo cream all over the face
Adapalene gel with placebo moisturizer: Placebo: 2 fingertip unit to cover all over the face twice a day.
Adapalene gel: 2 fingertip unit to cover all over the face before going to bed</description>
        </group>
        <group group_id="B3">
          <title>Adapalene Gel With Eucerin</title>
          <description>Morning
Wash face by prepared facial foam and dry their face
Apply Eucerin cream all over the face
Evening
Wash face by prepared facial foam and dry your face
Apply adapalene gel all over the face
Apply Eucerin cream all over the face
Adapalene gel with Eucerin: Eucerin: 2 fingertip unit to cover all over the face twice a day.
Adapalene gel: 2 fingertip unit to cover all over the face before going to bed</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="40"/>
            <count group_id="B4" value="120"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.3" lower_limit="19" upper_limit="43"/>
                    <measurement group_id="B2" value="27.2" lower_limit="20" upper_limit="40"/>
                    <measurement group_id="B3" value="28.1" lower_limit="18" upper_limit="49"/>
                    <measurement group_id="B4" value="27.5" lower_limit="18" upper_limit="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="67"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Thailand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Reduction of Undesirable Effects</title>
        <description>Undesirable effects were evaluated from skin's condition/signs(erythema, dryness and scaling) are evaluated by dermatologist. (none; mild; moderate; severe) and subject interview/symptoms(stinging/burning and pruritis) are evaluated by participants.(none; mild; moderate; severe). There were assessed at 2nd week, 4th week, and 8th week.
The worst score of each parameter which was defined as the worst local tolerance score is demonstrated and compared among 3 groups as shown.</description>
        <time_frame>2nd week, 4th week, and 8th week</time_frame>
        <population>The reasons for drop out were lack of compliance (n=1, group A: adapalene gel alone) and consent withdrawal at patient's request (n=1, group C: adapalene with Eucerin)</population>
        <group_list>
          <group group_id="O1">
            <title>Adapalene Gel</title>
            <description>Evening
Wash face by prepared facial foam and dry your face
Apply adapalene gel all over the face
Adapalene gel: Adapalene gel: 2 fingertip unit to cover all over the face before going to bed</description>
          </group>
          <group group_id="O2">
            <title>Adapalene Gel With Placebo Moisturizer</title>
            <description>Morning
Wash face by prepared facial foam and dry their face
Apply placebo cream all over the face
Evening
Wash face by prepared facial foam and dry your face
Apply adapalene gel all over the face
Apply placebo cream all over the face
Adapalene gel with placebo moisturizer: Placebo: 2 fingertip unit to cover all over the face twice a day.
Adapalene gel: 2 fingertip unit to cover all over the face before going to bed</description>
          </group>
          <group group_id="O3">
            <title>Adapalene Gel With Eucerin</title>
            <description>Morning
Wash face by prepared facial foam and dry their face
Apply Eucerin cream all over the face
Evening
Wash face by prepared facial foam and dry your face
Apply adapalene gel all over the face
Apply Eucerin cream all over the face
Adapalene gel with Eucerin: Eucerin: 2 fingertip unit to cover all over the face twice a day.
Adapalene gel: 2 fingertip unit to cover all over the face before going to bed</description>
          </group>
        </group_list>
        <measure>
          <title>Reduction of Undesirable Effects</title>
          <description>Undesirable effects were evaluated from skin's condition/signs(erythema, dryness and scaling) are evaluated by dermatologist. (none; mild; moderate; severe) and subject interview/symptoms(stinging/burning and pruritis) are evaluated by participants.(none; mild; moderate; severe). There were assessed at 2nd week, 4th week, and 8th week.
The worst score of each parameter which was defined as the worst local tolerance score is demonstrated and compared among 3 groups as shown.</description>
          <population>The reasons for drop out were lack of compliance (n=1, group A: adapalene gel alone) and consent withdrawal at patient's request (n=1, group C: adapalene with Eucerin)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Erythema (none)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="38"/>
                    <measurement group_id="O3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema (mild)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema (moderate)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dryness (none)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dryness (mild)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dryness (moderate)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Scaling (none)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Scaling (mild)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Scaling (moderate)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stinging (none)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stinging (mild)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stinging (moderate)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stinging (severe)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pruritus (none)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pruritus (mild)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pruritus (moderate)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pruritus (severe)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <p_value_desc>This statistical analysis was used to compare number of participants who had erythema among 3 groups.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.016</p_value>
            <p_value_desc>This statistical analysis was used to compare number of participants who had dryness among 3 groups</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.025</p_value>
            <p_value_desc>This statistical analysis was used to compare number of participants who had scaling among 3 groups.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.571</p_value>
            <p_value_desc>This statistical analysis was used to compare number of participants who had stinging among 3 groups.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.449</p_value>
            <p_value_desc>This statistical analysis was used to compare number of participants who had pruritus among 3 groups.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reduction of Severity of Acne</title>
        <description>Evaluation from mean counts of inflammatory, noninflammatory, and total acne lesions at baseline, and at 2, 4, and 8 weeks
Total acne lesions = inflammatory + noninflammatory acne lesions
Reduction of lesions counts are considered to be a better outcome</description>
        <time_frame>baseline, 2nd week, 4th week and 8th week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Adapalene Gel</title>
            <description>Evening
Wash face by prepared facial foam and dry your face
Apply adapalene gel all over the face
Adapalene gel: Adapalene gel: 2 fingertip unit to cover all over the face before going to bed</description>
          </group>
          <group group_id="O2">
            <title>Adapalene Gel With Placebo Moisturizer</title>
            <description>Morning
Wash face by prepared facial foam and dry their face
Apply placebo cream all over the face
Evening
Wash face by prepared facial foam and dry your face
Apply adapalene gel all over the face
Apply placebo cream all over the face
Adapalene gel with placebo moisturizer: Placebo: 2 fingertip unit to cover all over the face twice a day.
Adapalene gel: 2 fingertip unit to cover all over the face before going to bed</description>
          </group>
          <group group_id="O3">
            <title>Adapalene Gel With Eucerin</title>
            <description>Morning
Wash face by prepared facial foam and dry their face
Apply Eucerin cream all over the face
Evening
Wash face by prepared facial foam and dry your face
Apply adapalene gel all over the face
Apply Eucerin cream all over the face
Adapalene gel with Eucerin: Eucerin: 2 fingertip unit to cover all over the face twice a day.
Adapalene gel: 2 fingertip unit to cover all over the face before going to bed</description>
          </group>
        </group_list>
        <measure>
          <title>Reduction of Severity of Acne</title>
          <description>Evaluation from mean counts of inflammatory, noninflammatory, and total acne lesions at baseline, and at 2, 4, and 8 weeks
Total acne lesions = inflammatory + noninflammatory acne lesions
Reduction of lesions counts are considered to be a better outcome</description>
          <units>Lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Total Lesion Count</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.9" spread="49.1"/>
                    <measurement group_id="O2" value="27.4" spread="37.0"/>
                    <measurement group_id="O3" value="25.5" spread="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 Total Lesion Count</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41" spread="65.7"/>
                    <measurement group_id="O2" value="26.6" spread="29.3"/>
                    <measurement group_id="O3" value="23.8" spread="16.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 Total Lesion Count</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39" spread="54.2"/>
                    <measurement group_id="O2" value="27.3" spread="25.2"/>
                    <measurement group_id="O3" value="25.7" spread="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 Total Lesion Count</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.9" spread="33.3"/>
                    <measurement group_id="O2" value="26.8" spread="22.5"/>
                    <measurement group_id="O3" value="19.9" spread="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Inflammatory Lesion Counts</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="3.9"/>
                    <measurement group_id="O2" value="3" spread="2.6"/>
                    <measurement group_id="O3" value="3.8" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 Inflammatory Lesion Counts</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" spread="6.6"/>
                    <measurement group_id="O2" value="4.1" spread="7.4"/>
                    <measurement group_id="O3" value="3.6" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 Inflammatory Lesion Counts</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="5.4"/>
                    <measurement group_id="O2" value="2.9" spread="2.9"/>
                    <measurement group_id="O3" value="3.4" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 Inflammatory Lesion Counts</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="5.6"/>
                    <measurement group_id="O2" value="3.1" spread="4.1"/>
                    <measurement group_id="O3" value="2.4" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Noninflammatory Counts</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.4" spread="48.0"/>
                    <measurement group_id="O2" value="24.5" spread="37.3"/>
                    <measurement group_id="O3" value="21.6" spread="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 Noninflammatory Counts</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.5" spread="61.9"/>
                    <measurement group_id="O2" value="22.5" spread="28.1"/>
                    <measurement group_id="O3" value="20.5" spread="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 Noninflammatory Counts</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.4" spread="50.6"/>
                    <measurement group_id="O2" value="24.4" spread="24.4"/>
                    <measurement group_id="O3" value="22.6" spread="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 Noninflammatory Counts</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.4" spread="29.1"/>
                    <measurement group_id="O2" value="23.7" spread="20.1"/>
                    <measurement group_id="O3" value="17.7" spread="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.059</p_value>
            <p_value_desc>This statistical analysis was used to evaluate the change in total lesion counts at baseline and 8th week</p_value_desc>
            <method>wilcoxan signed ranks test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.697</p_value>
            <p_value_desc>This statistical analysis was used to evaluate the change in total lesion counts at baseline and 8th week</p_value_desc>
            <method>wilcoxan signed ranks test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.028</p_value>
            <p_value_desc>This statistical analysis was used to evaluate the change in total lesion counts at baseline and 8th week.</p_value_desc>
            <method>wilcoxan signed ranks test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <p_value_desc>This statistical analysis was used to evaluate the change in inflammatory lesion counts at baseline and 8th week.</p_value_desc>
            <method>wilcoxan signed ranks test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.755</p_value>
            <p_value_desc>This statistical analysis was used to evaluate the change in inflammatory lesion counts at baseline and 8th week.</p_value_desc>
            <method>wilcoxan signed ranks test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <p_value_desc>This statistical analysis was used to evaluate the change in inflammatory lesion counts at baseline and 8th week.</p_value_desc>
            <method>wilcoxan signed ranks test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.205</p_value>
            <p_value_desc>This statistical analysis was used to evaluate the change in non inflammatory lesion counts at baseline and 8th week.</p_value_desc>
            <method>wilcoxan signed ranks test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.576</p_value>
            <p_value_desc>This statistical analysis was used to evaluate the change in non inflammatory lesion counts at baseline and 8th week.</p_value_desc>
            <method>wilcoxan signed ranks test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.160</p_value>
            <p_value_desc>This statistical analysis was used to evaluate the change in non inflammatory lesion counts at baseline and 8th week.</p_value_desc>
            <method>wilcoxan signed ranks test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Skin Tolerability: Skin Sebum Content and Skin Hydration</title>
        <description>Skin tolerability was assessed by measuring the skin surface sebum content, skin hydration with the Sebumeter SM815 and Corneometer CM825, respectively</description>
        <time_frame>Skin tolerability was assessed at baseline and week 8. The changes of skin tolerability between baseline and 8th week of the 3 groups were compared.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Adapalene Gel</title>
            <description>Evening
Wash face by prepared facial foam and dry your face
Apply adapalene gel all over the face
Adapalene gel: Adapalene gel: 2 fingertip unit to cover all over the face before going to bed</description>
          </group>
          <group group_id="O2">
            <title>Adapalene Gel With Placebo Moisturizer</title>
            <description>Morning
Wash face by prepared facial foam and dry their face
Apply placebo cream all over the face
Evening
Wash face by prepared facial foam and dry your face
Apply adapalene gel all over the face
Apply placebo cream all over the face
Adapalene gel with placebo moisturizer: Placebo: 2 fingertip unit to cover all over the face twice a day.
Adapalene gel: 2 fingertip unit to cover all over the face before going to bed</description>
          </group>
          <group group_id="O3">
            <title>Adapalene Gel With Eucerin</title>
            <description>Morning
Wash face by prepared facial foam and dry their face
Apply Eucerin cream all over the face
Evening
Wash face by prepared facial foam and dry your face
Apply adapalene gel all over the face
Apply Eucerin cream all over the face
Adapalene gel with Eucerin: Eucerin: 2 fingertip unit to cover all over the face twice a day.
Adapalene gel: 2 fingertip unit to cover all over the face before going to bed</description>
          </group>
        </group_list>
        <measure>
          <title>Skin Tolerability: Skin Sebum Content and Skin Hydration</title>
          <description>Skin tolerability was assessed by measuring the skin surface sebum content, skin hydration with the Sebumeter SM815 and Corneometer CM825, respectively</description>
          <units>Âµg/cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Sebumeter</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.7" spread="34.4"/>
                    <measurement group_id="O2" value="71.2" spread="42.4"/>
                    <measurement group_id="O3" value="73.7" spread="31.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 Sebumeter</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.6" spread="31.7"/>
                    <measurement group_id="O2" value="59.9" spread="55.3"/>
                    <measurement group_id="O3" value="64.2" spread="35.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Corneometer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.7" spread="10.0"/>
                    <measurement group_id="O2" value="50.2" spread="10.5"/>
                    <measurement group_id="O3" value="46.7" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 Corneometer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.9" spread="10.9"/>
                    <measurement group_id="O2" value="49.5" spread="9.4"/>
                    <measurement group_id="O3" value="48.6" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.078</p_value>
            <p_value_desc>This statistical analysis was used to evaluate the change in skin sebum content at baseline and 8th week of the Adapalene gel group</p_value_desc>
            <method>Paired t-test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.167</p_value>
            <p_value_desc>This statistical analysis was used to evaluate the change in skin sebum content at baseline and 8th week of the Adapalene gel with placebo moisturizer group</p_value_desc>
            <method>Paired t-test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.134</p_value>
            <p_value_desc>This statistical analysis was used to evaluate the change in skin sebum content at baseline and 8th week of the Adapalene gel with Eucerin group</p_value_desc>
            <method>Paired t-test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.978</p_value>
            <p_value_desc>This statistical analysis was used to evaluate the change in skin hydration at baseline and 8th week of the Adapalene gel group</p_value_desc>
            <method>Paired t-test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.273</p_value>
            <p_value_desc>This statistical analysis was used to evaluate the change in skin hydration at baseline and 8th week of the Adapalene gel with placebo moisturizer group</p_value_desc>
            <method>Paired t-test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.735</p_value>
            <p_value_desc>This statistical analysis was used to evaluate the change in skin hydration at baseline and 8th week of the Adapalene gel with Eucerin group.</p_value_desc>
            <method>Paired t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Skin Tolerability: Transepidermal Water Loss (TEWL)</title>
        <description>Skin tolerability was assessed by measuring TEWL with the Tewameter TM300</description>
        <time_frame>Skin tolerability was assessed at baseline and week 8. The changes of skin tolerability between baseline and 8th week of the 3 groups were compared.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Adapalene Gel</title>
            <description>Evening
Wash face by prepared facial foam and dry your face
Apply adapalene gel all over the face
Adapalene gel: Adapalene gel: 2 fingertip unit to cover all over the face before going to bed</description>
          </group>
          <group group_id="O2">
            <title>Adapalene Gel With Placebo Moisturizer</title>
            <description>Morning
Wash face by prepared facial foam and dry their face
Apply placebo cream all over the face
Evening
Wash face by prepared facial foam and dry your face
Apply adapalene gel all over the face
Apply placebo cream all over the face
Adapalene gel with placebo moisturizer: Placebo: 2 fingertip unit to cover all over the face twice a day.
Adapalene gel: 2 fingertip unit to cover all over the face before going to bed</description>
          </group>
          <group group_id="O3">
            <title>Adapalene Gel With Eucerin</title>
            <description>Morning
Wash face by prepared facial foam and dry their face
Apply Eucerin cream all over the face
Evening
Wash face by prepared facial foam and dry your face
Apply adapalene gel all over the face
Apply Eucerin cream all over the face
Adapalene gel with Eucerin: Eucerin: 2 fingertip unit to cover all over the face twice a day.
Adapalene gel: 2 fingertip unit to cover all over the face before going to bed</description>
          </group>
        </group_list>
        <measure>
          <title>Skin Tolerability: Transepidermal Water Loss (TEWL)</title>
          <description>Skin tolerability was assessed by measuring TEWL with the Tewameter TM300</description>
          <units>g/m^2h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline TEWL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.8" spread="3.3"/>
                    <measurement group_id="O2" value="10.4" spread="4.6"/>
                    <measurement group_id="O3" value="10.6" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 TEWL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.3" spread="4.8"/>
                    <measurement group_id="O2" value="11.8" spread="5.4"/>
                    <measurement group_id="O3" value="11.5" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <p_value_desc>This statistical analysis was used to evaluate the change in TEWL at baseline and 8th week of the Adapalene gel group.</p_value_desc>
            <method>Paired t-test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <p_value_desc>This statistical analysis was used to evaluate the change in TEWL at baseline and 8th week of the Adapalene gel with placebo moisturizer group.</p_value_desc>
            <method>Paired t-test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.123</p_value>
            <p_value_desc>This statistical analysis was used to evaluate the change in TEWL at baseline and 8th week of the Adapalene gel with Eucerin group.</p_value_desc>
            <method>Paired t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reduction of Severity of Acne: Acne Severity Index (ASI)</title>
        <description>The ASI score was calculated from the number of papules + (2 x pustules) + (comedones/4)
Decrease of ASI score are considered to be a better outcome</description>
        <time_frame>baseline, 2nd week, 4th week and 8th week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Adapalene Gel</title>
            <description>Evening
Wash face by prepared facial foam and dry your face
Apply adapalene gel all over the face
Adapalene gel: Adapalene gel: 2 fingertip unit to cover all over the face before going to bed</description>
          </group>
          <group group_id="O2">
            <title>Adapalene Gel With Placebo Moisturizer</title>
            <description>Morning
Wash face by prepared facial foam and dry their face
Apply placebo cream all over the face
Evening
Wash face by prepared facial foam and dry your face
Apply adapalene gel all over the face
Apply placebo cream all over the face
Adapalene gel with placebo moisturizer: Placebo: 2 fingertip unit to cover all over the face twice a day.
Adapalene gel: 2 fingertip unit to cover all over the face before going to bed</description>
          </group>
          <group group_id="O3">
            <title>Adapalene Gel With Eucerin</title>
            <description>Morning
Wash face by prepared facial foam and dry their face
Apply Eucerin cream all over the face
Evening
Wash face by prepared facial foam and dry your face
Apply adapalene gel all over the face
Apply Eucerin cream all over the face
Adapalene gel with Eucerin: Eucerin: 2 fingertip unit to cover all over the face twice a day.
Adapalene gel: 2 fingertip unit to cover all over the face before going to bed</description>
          </group>
        </group_list>
        <measure>
          <title>Reduction of Severity of Acne: Acne Severity Index (ASI)</title>
          <description>The ASI score was calculated from the number of papules + (2 x pustules) + (comedones/4)
Decrease of ASI score are considered to be a better outcome</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline ASI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.7" spread="13.6"/>
                    <measurement group_id="O2" value="9.4" spread="9.5"/>
                    <measurement group_id="O3" value="9.5" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 ASI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.4" spread="20.8"/>
                    <measurement group_id="O2" value="10.4" spread="11.3"/>
                    <measurement group_id="O3" value="8.7" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 ASI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.6" spread="19.4"/>
                    <measurement group_id="O2" value="9.2" spread="7.5"/>
                    <measurement group_id="O3" value="9.2" spread="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 ASI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" spread="13.7"/>
                    <measurement group_id="O2" value="9.3" spread="8.5"/>
                    <measurement group_id="O3" value="7.1" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <p_value_desc>This statistical analysis was used to evaluate the change in ASI score at baseline and 8th week.</p_value_desc>
            <method>wilcoxan signed ranks test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.606</p_value>
            <p_value_desc>This statistical analysis was used to evaluate the change in ASI score at baseline and 8th week.</p_value_desc>
            <method>wilcoxan signed ranks test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <p_value_desc>This statistical analysis was used to evaluate the change in ASI score at baseline and 8th week.</p_value_desc>
            <method>wilcoxan signed ranks test</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Adapalene Gel</title>
          <description>Evening
Wash face by prepared facial foam and dry your face
Apply adapalene gel all over the face
Adapalene gel: Adapalene gel: 2 fingertip unit to cover all over the face before going to bed</description>
        </group>
        <group group_id="E2">
          <title>Adapalene Gel With Placebo Moisturizer</title>
          <description>Morning
Wash face by prepared facial foam and dry their face
Apply placebo cream all over the face
Evening
Wash face by prepared facial foam and dry your face
Apply adapalene gel all over the face
Apply placebo cream all over the face
Adapalene gel with placebo moisturizer: Placebo: 2 fingertip unit to cover all over the face twice a day.
Adapalene gel: 2 fingertip unit to cover all over the face before going to bed</description>
        </group>
        <group group_id="E3">
          <title>Adapalene Gel With Eucerin</title>
          <description>Morning
Wash face by prepared facial foam and dry their face
Apply Eucerin cream all over the face
Evening
Wash face by prepared facial foam and dry your face
Apply adapalene gel all over the face
Apply Eucerin cream all over the face
Adapalene gel with Eucerin: Eucerin: 2 fingertip unit to cover all over the face twice a day.
Adapalene gel: 2 fingertip unit to cover all over the face before going to bed</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Papapit Tuchinda</name_or_title>
      <organization>Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University</organization>
      <phone>+662-419-4333</phone>
      <email>papapitt@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

